Atlas Trials

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

Clinical trial NCT03898791 · COMPLETED

Trial details

NCT number
NCT03898791
Sponsor
Eli Lilly and Company
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Small Cell Lung Cancer
Start date
2019-07-16
Primary completion
2020-06-02
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.